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Abstract: In chronic obstructive pulmonary disease (COPD) patients tiotropium bromide has 
been shown to improve forced expiratory volume in one second (FEV1) and inspiratory capac-
ity (IC). We investigated whether the mechanism leading to these improvements is related to 
small airways ventilation heterogeneity, assessed by multiple breath washout tests. Forty stable 
tiotropium-free COPD patients (FEV1: 27%–78% predicted) were studied before and 90 min 
after administration of tiotropium bromide on visit0, and following 3 and 6 weeks of tiotropium 
bromide treatment (visit3wks, visit6wks). After study completion, COPD patients were classiﬁ  ed 
into two subgroups according to degree of hyperinﬂ  ation at visit0 (Hyp–, Hyp+). The Hyp+ 
group showed signiﬁ  cant increases in trough (ie, pre-dose) FEV1 and IC after 3 and 6 weeks of 
tiotropium bromide, and the 90 min tiotropium bromide responses of FEV1 and IC were sig-
niﬁ  cant at visit0 (p ≤ 0.001 for both) but not during subsequent visits. The Hyp- group showed 
signiﬁ  cant FEV1 increases 90 min after tiotropium bromide on all three visits (all p   0.005) but 
no sustained increase in trough values. In both COPD subgroups, the grossly abnormal ventila-
tion heterogeneity barely showed any signiﬁ  cant improvements with tiotropium bromide in the 
conductive airways (without changes in trough value) and no changes at all in the acinar airways. 
We conclude that the sustained improvements in trough IC and FEV1 with tiotropium bromide 
predominantly observed in COPD patients with considerable hyperinﬂ  ation, are unrelated to 
small airways ventilation heterogeneity.
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Introduction
Several clinical trials have investigated the effect of the long-acting anticholinergic 
bronchodilator, tiotropium bromide (Barnes et al 1995), on lung function and dyspnea 
at rest (van Noord et al 2000; Vincken et al 2002; Casaburi et al 2002; Celli et al 2003; 
Brusasco et al 2003; Verkindre et al 2006) and during exercise (O’Donnell et al 2004; 
Casaburi et al 2005; Maltais et al 2005), and assessed its inﬂ  uence on quality of life 
(Vincken et al 2002; Casaburi et al 2002; Brusasco et al 2003; Casaburi et al 2005; 
Verkindre et al 2006) or on the occurrence of exacerbations (Vincken et al 2002; 
Niewoehner et al 2005; Dusser et al 2006) in chronic obstructive pulmonary disease 
(COPD). Most of these studies indicated signiﬁ  cant and sustained improvements of 
the primary outcome parameters, and consistently reported improvements in forced 
expiratory volume in one second (FEV1) and/or inspiratory capacity (IC) after different 
tiotropium bromide treatment periods up to one year. Given that tiotropium bromide 
is thought to act through its selective and prolonged binding to M3 receptors (Gross 
2004), which are predominantly located in the large and medium-sized airways (Barnes 
2004), it could a priori be expected that the improvement in airway function would be 
mainly located in these larger conductive airways. While the observed FEV1 improve-
ments could be brought in agreement with this proposition, the IC improvements have International Journal of COPD 2007:2(4) 626
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prompted several authors to hint at the implication of small 
airways in this anticholinergic bronchodilation process (van 
Noord et al 2000; Verkindre et al 2006).
We have recently shown that COPD patients are 
characterized by a combination of both large and small 
conductive airways ventilation heterogeneity, as opposed 
to smokers with similar smoking history but without COPD 
in whom only small airways are affected (Verbanck et al 
2004). This was measured with a model-based analysis of 
the multiple breath washout test which delivers independent 
phase III slope-derived indices of ventilation heterogeneity 
originating in the conductive and acinar lung zone (Scond and 
Sacin, respectively) (Verbanck et al 1997, 1998). In an earlier 
study, COPD patients have shown no signiﬁ  cant response of 
Scond or Sacin to 400 μg of salbutamol with a small spacer 
inhalation aid (Verbanck et al 1999). In the present study, 
we use Scond and Sacin measurements to test the hypoth-
esis that the small airways situated in the conductive and/or 
proximal acinar lung zones could participate to some degree 
in the tiotropium bromide response and thus affect inspiratory 
capacity, which is linked to dyspnea and exercise limitation 
in COPD patients (O’Donnell et al 2004). In particular, this 
mechanistic study aims to investigate whether the reported 
beneﬁ  cial effects on pre-dose (trough) and peak values of 
FEV1 and IC are paralleled by improvements in small air-
ways heterogeneity. In order to assess whether any potential 
improvement in small airways ventilation heterogeneity was 
speciﬁ  cally linked to improvement in hyperinﬂ  ation, we 
deliberately included COPD patients with varying degrees 
of hyperinﬂ  ation at baseline (which is also representative of 
a real-life clinical situation).
Material and methods
Patients and procedures
The study protocol was approved by the local ethics com-
mittee. Forty patients with a clinical diagnosis of COPD for 
at least 2 years were recruited if they fulﬁ  lled the following 
inclusion criteria: aged over 40 years, smoking history of 
at least 15 packyears, FEV1/forced vital capacity (FVC)   
70% and post bronchodilator FEV1   80%pred. Patients 
with a history of concomitant asthma or atopy or patients 
requiring supplemental oxygen therapy were excluded. 
None of the patients had suffered any exacerbation in the 
six month period prior to the study, nor any recent upper 
respiratory tract infection. The COPD patients already on 
tiotropium bromide treatment were asked to discontinue 
tiotropium for at least 4 weeks before the screening visit. 
A written informed consent was obtained from all partici-
pating patients. Patients had been requested not to take any 
short- or long-acting bronchodilator medication for at least 
8 h and 24 h, respectively, before each visit. There was 1 
screening visit and 3 visits further referred to as study visits, 
ie, a baseline visit (visit0) and two visits after respectively 
3 and 6 weeks (visit3wks and visit6wks) of tiotropium bromide 
therapy (18 μg dry powder inhaled via the HandiHalerR 
device once daily in the morning). On visit3wks and visit6wks, 
the last tiotropium bromide intake was on the morning 
preceding the study day.
On the screening visit, patients underwent lung function 
and ventilation distribution testing according to standard-
ized procedures. Lung function included spirometry and 
plethysmographic measurement of speciﬁ  c airway conduct-
ance (sGaw) and IC (ICpl). Given the potential problems 
with plethysmographic volume determination in the case 
of obstructed patients (Rodenstein and Stanescu 1982), 
we also used the preferred method of IC computation (ie, 
the difference between open circuit functional residual and 
total lung capacity volume levels). For the computation and 
interpretation of ventilation heterogeneity indices Scond 
and Sacin, we refer to a previous description (Verbanck 
et al 1997), which is brieﬂ  y summarized in the Appendix. 
The screening visit served to characterize patients in terms 
of lung function and ventilation heterogeneity, and to 
assess their room for reversibility by the combination of 
a short-acting anticholinergic and a fast-acting β2-agonist 
drug. Sixty minutes after inhalation of 80 μg of ipratropium 
bromide, an intermediate spirometry was performed, and 
additional bronchodilation was elicited by inhaling 400 μg 
of salbutamol. After another 30 min (ie, cumulative post-
bronchodilator time: 90 min),lung function and ventilation 
distribution testing was repeated.
On the baseline study visit (visit0), patients ﬁ  rst under-
went lung function and ventilation distribution testing, and 
were then instructed to inhale 18 μg of tiotropium bromide 
dry powder via the HandiHaler® device for the ﬁ  rst time. 
After 60 min, intermediate spirometry was performed, 
and after 90 min, the study visit was concluded with lung 
function and ventilation distribution testing. The next two 
study visits (visit3wks and visit6wks), after respectively 3 and 
6 weeks of daily tiotropium bromide treatment, involved 
exactly the same procedure as that on visit0. Given that for 
these two study visits, the last tiotropium bromide intake had 
been on the morning preceding the study day, the 90 min 
effect of tiotropium bromide could be assessed on trough 
values of lung function and ventilation heterogeneity in the 
laboratory.International Journal of COPD 2007:2(4) 627
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On each visit, patients rated their dyspnea on a visual 
analogue scale (VAS) and by means of the Medical 
Research Council (MRC) scale (ranging 1–5). Finally, 
patients also filled out a symptom score sheet for 
wheezing, shortness of breath, cough, and chest tight-
ness ranging “not present”,“mild”,”moderate”,“severe” 
(scored 0–3 and summed to a total symptom score rang-
ing 0–12).
Statistical analysis
Two-way repeated measures analysis of variance (ANOVA) 
(Statistica5.5, StatSoft, Tulsa, OK) was used to detect 
any differences between the 3 study visits prior to and 90 
min after tiotropium bromide administration (2 factors: 
inter-visit and intra-visit tiotropium bromide effect). One-
way repeated measures ANOVA was used to detect any 
inter-visit differences on the symptom scores. Bonferroni 
adjustment was used to test for post-hoc differences. Spear-
man rank correlations were performed between changes in 
symptom or dyspnea scores and changes in lung function 
indices.
Results
The 40 patients (36M/4F) participating in this study were 
stable COPD patients on maintenance treatment mostly 
involving inhaled steroids (37/40) in combination with 
long-acting β2-agonists (37/40). All patients were also on 
a combination of short-acting β2-agonists and ipratropium 
bromide, but at study entry, ipratropium bromide was 
discontinued. Eight out of 40 patients were current smokers. 
Figure 1 shows a histogram of the residual volume over total 
lung capacity ratio (RV/TLC) measured at the screening visit 
before bronchodilator administration, in the patient group 
under study (n = 40). The median RV/TLC being 54.8%, 
the group was split into a subgroup with a high degree of 
hyperinﬂ  ation if RV/TLC   55% (Hyp+; n = 20) and a sub-
group with a low degree of hyperinﬂ  ation if RV/TLC   55% 
(Hyp– ; n = 20).
Table 1 shows lung function, ventilation heterogeneity 
and symptom scores prior to tiotropium bromide admin-
istration on the study visits visit0, visit3wks and visit6wks. 
For each parameter in Table 1, change from baseline 
(Δ) was computed as the difference between the value 
of visit6wks and that of baseline visit0 in order to test for 
correlations of change. In the Hyp– group, none of the 
correlations between changes in symptom or dyspnea 
scores and changes in lung function parameters were 
signiﬁ  cant (p   0.1 for all). In the Hyp+ group, changes 
in total symptom or MRC score did not correlate with 
any lung function or ventilation heterogeneity changes 
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Figure 1 Histogram of the distribution of the residual volume (RV) over total lung capacity (TLC) ratio in the COPD group under study (n = 40). The 4 left-most bars 
constitute the Hyp  group (n = 20) and the 3 right-most bars constitute the Hyp+ group (n = 20).International Journal of COPD 2007:2(4) 628
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(p   0.1 for all). However, ΔVAS did correlate with ΔIC 
(r = –0.54; p = 0.016) and also with ΔsGaw (r = –0.49; 
p = 0.03) (Figure 2). Figure 2B clearly identiﬁ  es an out-
lier at ΔsGaw = –0.055 cm–1H2O • s–1 (open circle); upon 
detailed inspection, this was due to the plethysmographic 
determination of lung volume but there was no objective 
reason for exclusion.
Panels A in Figures 3–6 illustrate, for the Hyp+ group, 
inter- and intra-visit changes in FEV1, IC, Scond, or sGaw, 
ie, those parameters of Table 1 showing any signiﬁ  cant inter- 
or intra-visit change in this subgroup. Panels B in Figures 
3–6 display the corresponding data for the Hyp– group.
In the Hyp+ group, FEV1 (Figure 3A) and IC (Figure 
4A) signiﬁ  cantly increased 90 min after the ﬁ  rst 18 μg 
tiotropium bromide dose on visit0 (p   0.001 for both), 
while no such intra-visit increases occurred during visit3wks 
and visit6wks (p   0.1 for both). Intra-visit changes in 
sGaw (Figure 5A) showed a similarity with FEV1 and IC 
behavior, in that sGaw also increased signiﬁ  cantly during 
the baseline visit0 (p   0.001) but not during visit3wks or 
visit6wks (p   0.1). While Figure5A suggests an increase 
in trough sGaw value, this was not signiﬁ  cant (p > 0.05 
for both), yet, when excluding the abovementioned out-
lier (Figure 2B; open circle), trough sGaw did increase 
signiﬁ  cantly from 0.038 cm–1H2O • s–1 (visit0) to 0.045 
cm–1H2O • s–1 (visit3wks; p = 0.007) and 0.044 cm–1H2O • 
s–1 (visit6wks; p = 0.04). While Figure 6A indicates tenden-
cies for intra-visit Scond decreases (ie, improvements) 
of the same order as that observed on the screening visit, 
averaging an 11% decrease over the three study visits, the 
Scond decrease only reached statistical signiﬁ  cance on 
the last visit (p = 0.02). The complementary indicators of 
small airway function, end-expiratory ﬂ  ow after 75% of 
forced expired vital capacity (FEF75) and Sacin, did not 
present any inter- or intra-visit effect in this subgroup 
(p > 0.1 for all).
Table 1 Characteristics of COPD subgroups with RV/TLC   55% (Hyp+) OR <55% (Hyp−) and the effect of tiotropium
 Hyp+ (n = 20)  Hyp– (n = 20)  p-value
     Hyp+ vs Hyp–
     at  baseline
Age (yrs)  68 ± 2  65 ± 2   0.1
Height (cm)  171 ± 1  177 ± 1  0.003
COPD diagnosis (yrs)  7 ± 1  6 ± 2   0.1
Packyears (py)  54 ± 4  49 ± 7   0.1
  Baseline  3 wks   6 wks   Baseline  3 wks   6 wks
   tiotropium  tiotropium    tiotropium  tiotropium
FEV1 (%pred)  50 ± 3  55 ± 3†  55 ± 3†  60 ± 3  61 ± 3  62 ± 3  0.006
FEV1 (L)  1.38 ± 0.07  1.52 ± 0.06†  1.52 ± 0.07†  1.94 ± 0.10  1.97 ± 0.11  1.99 ± 0.11   0.001
FEV1/FVC (%)  46 ± 2  47 ± 2  47 ± 2  51 ± 2  50 ± 2  50 ± 2   0.1
FEF75 (%pred)  13 ± 1  13 ± 1  13 ± 1  18 ± 1  17 ± 1  18 ± 1  0.008
Kco (%pred)  69 ± 5  69 ± 5  69 ± 5  71 ± 4  69 ± 4  70 ± 5   0.1
sGaw (L/s/cmH2O/L) 0.042  ± 0.005  0.046 ± 0.003  0.045 ± 0.004  0.049 ± 0.004  0.049 ± 0.003  0.049 ± 0.003   0.1
RVpl (ml)  3811 ± 159  3877 ± 204  3650 ± 121  3052 ± 137  3086 ± 150  2991 ± 153  0.001
TLCpl (ml)  6644 ± 243  6832 ± 252  6707 ± 221  6600 ± 207  6704 ± 246  6628 ± 240   0.1
ICpl (ml)  1889 ± 95  1956 ± 84  2026 ± 119  2392 ± 148  2367 ± 141  2428 ± 140  0.007
IC (ml) 2181  ± 126  2386 ± 122*  2434 ± 130†  2665 ± 113  2679 ± 119  2693 ± 129  0.007
Sacin (L−1) 0.425  ± 0.024  0.399 ± 0.025  0.411 ± 0.024  0.339 ± 0.030  0.365 ± 0.032  0.340 ± 0.033  0.03
Scond (L−1) 0.086  ± 0.006  0.083 ± 0.007  0.090 ± 0.008  0.086 ± 0.007  0.081 ± 0.007  0.095 ± 0.008   0.1
FRCmbw (ml)  3752 ± 125  3665 ± 131  3595 ± 118  3680 ± 150  3674 ± 146  3659 ± 126   0.1
Total symptom score  3.5 ± 0.4  2.4 ± 0.4†  1.5 ± 0.2†  3.6 ± 0.4  2.0 ± 0.3†  1.7 ± 0.3†   0.1
(0–12)
MRC dyspnea score  2.1 ± 0.2  2.0 ± 0.2  1.8 ± 0.2  1.7 ± 0.2  1.8 ± 0.2  1.9 ± 0.2   0.1
(1–5)
VAS dyspnea score  4.5 ± 0.5  3.2 ± 0.4*  2.7 ± 0.5†  3.0 ± 0.4  3.0 ± 0.5  2.7 ± 0.4  0.03
(0–10)
Notes: All averages (± SEM) refer to data prior to tiotropium intake on the study day. 
Abbreviations: FEV1, forced expired volume in one second; FVC, forced expired vital capacity; FEF75, forced expiratory ﬂ  ow after expiration of 75% FVC; Kco, carbon 
monoxide diffusing capacity per lung volume; sGaw, speciﬁ  c airway conductance; RVpl,TLCpl,ICpl, plethysmographic residual volume, total lung capacity, and inspiratory 
capacity; IC, inspiratory capacity measured in open circuit; Sacin,Scond, index of acinar and conductive ventilation heterogeneity (see text for details); FRCmbw, functional 
residual capacity derived from the multiple breath washout. For symptom and dyspnea scores (see text); Signiﬁ  cant changes from baseline (within Hyp+ and Hyp− groups): 
*p < 0.05; †p < 0.01.International Journal of COPD 2007:2(4) 629
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Figure 3 A: Forced expiratory volume in one second (FEV1) as %predicted obtained from the Hyp+ group on the screening visit (dotted line connecting open triangles; 
pre- and 90 min post-dilation with a combination of salbutamol and ipratropium bromide) and during the three study visits (solid lines connecting open circles (pre-) and 
closed circles (90 min post-) tiotropium); the crosses refer to intermediate FEV1 measures after 60 min. On the ﬁ  rst study visit, patients were tiotropium-free, while the 
other two study visits followed 3 and 6 weeks of tiotropium once-daily treatment with the last tiotropium intake on the day prior to the study visit; asterisks indicate any 
signiﬁ  cant change 90 min after tiotropium (2-way ANOVA with Bonferroni; p < 0.05). B: FEV1 obtained from the Hyp− group.
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Figure 2 A: Scatterplot of the individual change in IC (ΔIC) versus the corresponding change in visual analog dyspnea score (ΔVAS) in the Hyp+ group where ΔIC and 
ΔVAS are computed as the VAS or pre-tiotropium IC value at the 6 weeks tiotropium visit minus the VAS or pre-tiotropium IC value at the baseline study visit. B: Scatter-
plot of the individual change in sGaw (ΔsGaw) versus the corresponding change in visual analog score (ΔVAS) in the Hyp+ group; same representation as in A.
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The Hyp− group showed no improvements in trough 
values of any parameter after 3 or 6 weeks of tiotropium 
bromide treatment. Another striking difference of the Hyp− 
with respect to the Hyp+ group is that FEV1 (Figure 3B) 
and sGaw (Figure 5B) showed highly signiﬁ  cant intra-visit 
increases (p   0.01 for both) on all study visits. By contrast, 
IC (Figure 4B) only increased signiﬁ  cantly (p = 0.03) on 
the baseline visit (p   0.1 on visit3wks and visit6wks. While 
there were tendencies for intra-visit Scond decreases (ie, 
improvements) of the same order as that observed at the 
screening visit, averaging a 12% decrease over the three 
study visits, the Scond decrease failed to reach statistical 
signiﬁ  cance (visit6wks: p = 0.053). As in the Hyp+ group, 
FEF75 and Sacin did not present any inter- or intra-visit 
effect of tiotropium bromide in the Hyp– subgroup (p   0.1 
for all).
Two supplementary analyses were performed to verify 
whether the observed patterns, that appear to be speciﬁ  cally 
linked to the presence of hyperinﬂ  ation, were not a conse-
quence of (a) the expected difference in disease severity (in International Journal of COPD 2007:2(4) 630
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terms of FEV1) between Hyp+ and Hyp– subgroups,and (b) 
the arbitrary choice of the median RV/TLC as a cut-off (in 
casu: RV/TLC = 55%) for the classiﬁ  cation into Hyp+ and 
Hyp– subgroups. Hence we repeated the analysis of Table 1, 
but by considering FEV1 matched Hyp+ and Hyp– subgroups 
(n = 15; Table 2), and by considering Hyp+ and Hyp− 
subgroups (n = 10; Table 3) with only those patients cor-
responding to the 10 lowermost RV/TLC ( 46%) and 10 
uppermost RV/TLC ( 59%) values. Despite some differ-
ences, the outcome of both supplementary analyses of Tables 
2 and 3 was very similar to that observed for the entire COPD 
population in Table 1.
Discussion
This study shows a very distinct pattern of tiotropium 
bromide-induced improvement of airflow (FEV1) 
and IC between COPD patients with a high degree of 
hyperinflation (Hyp+) and COPD patients with low 
degree of hyperinflation (Hyp–), in that only the Hyp+ 
group showed significant increases in trough FEV1 and 
IC values. No such sustained improvement was observed 
for ventilation heterogeneity in either group. In fact, 
reduction in ventilation heterogeneity was confined to 
the conductive airway compartment, was of limited mag-
nitude, and followed a very similar pattern across both 
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Figure 5 A: Speciﬁ  c conductance (sGaw) obtained from the Hyp+ group on the screening visit (dotted line connecting open triangles; pre- and 90 min post-dilation 
with a combination of salbutamol and ipratropium bromide) and during the three study visits (solid lines connecting open circles (pre-) and closed circles (90 min post-) 
tiotropium). On the ﬁ  rst study visit, patients were tiotropium-free, while the other two study visits followed 3 and 6 weeks of tiotropium once-daily treatment with the last 
tiotropium intake on the day prior to the study visit; asterisks indicate any signiﬁ  cant change 90 min after tiotropium (2-way ANOVA with Bonferroni; p < 0.05). B: sGaw 
obtained from the Hyp− group.
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Figure 4 A: Inspiratory capacity measured in an open circuit (IC) obtained from the Hyp+ group on the screening visit (dotted line connecting open triangles; pre- and 
90 min post-dilation with a combination of salbutamol and ipratropium bromide) and during the three study visits (solid lines connecting open circles (pre-) and closed 
circles (90 min post-) tiotropium). On the ﬁ  rst study visit, patients were tiotropium-free, while the other two study visits followed 3 and 6 weeks of tiotropium once-
daily treatment with the last tiotropium intake on the day prior to the study visit; asterisks indicate any signiﬁ  cant change 90 min after tiotropium (2-way ANOVA with 
Bonferroni; p < 0.05); the dotted line represents the predicted IC value for this subgroup. B: IC obtained from the Hyp− group.International Journal of COPD 2007:2(4) 631
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COPD groups. The discrepancy between the behavior 
of IC and ventilation heterogeneity in the hyperinflated 
COPD subgroup, makes it unlikely that small airways are 
implicated in the sustained improvements of IC observed 
by us and others. The modest intra-visit Scond decreases 
(reaching p = 0.05 significance on only one occasion) 
imply that tiotropium bromide action is either affecting 
heterogeneity of the larger conductive airways (thus not 
affecting small airways heterogeneity) or acting in a very 
homogeneous way at the level of the small conductive 
airways (thus not affecting small airways heterogene-
ity). However, the absence of any FEF75 change with 
tiotropium bromide makes the latter possibility highly 
unlikely. Rather, the difference in patterns of sGaw 
improvements between Hyp– and Hyp+ groups, similar 
to that observed for IC and FEV1, suggests that larger 
airways or large lung units subtended by these large air-
ways play a major role in the short- and long-term effect 
of tiotropium bromide.
The sustained improvement of FEV1 and IC after 3 and 
6weeks of tiotropium bromide treatment only occurred in 
COPD patients with considerable hyperinﬂ  ation (Hyp+). 
Nevertheless, while the Hyp– patients showed no long-
term FEV1 or IC effects, their short-term FEV1 increases 
(90 min after tiotropium bromide) on each study visit were 
of the same magnitude as those obtained at baseline visit 
in Hyp+ patients. No such similarity between short-term 
improvements across both COPD subgroups was observed 
for IC. This indicates that the mechanism and site of 
bronchodilatation of tiotropium bromide (reﬂ  ected in FEV1) 
are essentially the same in both COPD groups, but that 
when considerable hyperinﬂ  ation is present, a continued 
bronchodilating action has the additional beneﬁ  t of relieving 
hyperinﬂ  ation (reﬂ  ected in an IC improvement). The similar 
degree of bronchodilation in both groups suggests that any 
potential effect of the baseline state of hyperinﬂ  ation on 
pulmonary distribution of the tiotropium bromide aerosol 
was negligible. In addition, the observed large airway effect 
suggests that either tiotropium bromide deposition was 
effectively conﬁ  ned to the large conductive airways, or that 
this was the only effective site of tiotropium bromide action 
on M3 receptors.
The trough IC and FEV1 values in the Hyp+ group 
after 3 and 6 weeks of tiotropium bromide treatment were 
indistinguishable from the respective peak values seen at 
the baseline visit 90 min after tiotropium bromide. This 
contrasts with previous studies (van Noord et al 2000; 
Vincken et al 2002; Brusasco et al 2003; Celli et al 2003; 
O’Donnell et al 2004; Maltais et al 2005; Niewoehner 
et al 2005; Verkindre et al 2006) where trough FEV1 
and/or IC generally increased to a value intermediate 
between baseline and peak value, such that study visits 
after several weeks of tiotropium bromide treatment still 
showed room for FEV1 or IC improvement. Three factors 
should be considered when comparing our study with 
previous ones. Firstly, over 90% of the COPD patients 
under study here were on a combination of a long-acting 
β2 agonist and inhaled steroid treatment, with tiotropium 
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bromide as an add-on study medication, as opposed to 
most previous studies where long-acting β2 agonists were 
not permitted. This may account for some quantitative 
differences of tiotropium bromide effects with respect to 
previous studies (here, typical changes in FEV1 trough 
value are 10% baseline in Hyp+ patients). Secondly, in 
those previous studies where hyperinflation was not part 
of the inclusion criteria, the COPD groups under study 
may have been a mixture of patients with a range of 
hyperinflation. One would then expect a pattern which 
is intermediate to that seen in our Hyp+ and Hyp– groups, 
corresponding to a partial increase in trough FEV1 and 
IC values between baseline and treatment visits, and an 
additional intra-visit increase from trough to peak FEV1 
or IC value. Thirdly, the method of IC measurement 
varied across previous tiotropium bromide studies, using 
the difference between spirometric volume levels cor-
responding to FRC and TLC (corresponding to IC here) 
or that derived from plethysmographic FRC and TLC 
measurements (corresponding to ICpl here). The pitfalls 
inherent to plethysmographic volume determination 
in COPD have been documented before (Rodenstein 
and Stanescu 1982) and the difference between IC 
and ICpl behavior across Tables 1 to 3 emphasizes the 
interpretation problems with plethysmographically deter-
mined lung volumes.
In conclusion, we have observed a pattern of improved 
airﬂ  ow (FEV1) and inspiratory lung capacity (IC) with 
tiotropium bromide in COPD patients, which was linked 
to their degree of hyperinﬂ  ation at baseline. In patients 
with a low degree of hyperinﬂ  ation, FEV1 and IC showed 
consistent increases, but no sustained changes in trough 
FEV1 or IC. By contrast, in COPD patients with consid-
erable hyperinﬂ  ation at baseline, 3 weeks of tiotropium 
bromide treatment elicited improvements in trough IC and 
FEV1, close to the maximum obtainable value. The con-
comitant sGaw changes suggest that the main therapeutic 
effect is elicited in the large conductive airways. Ventila-
tion heterogeneity of the acinar airways was unaffected 
by tiotropium bromide, and the modest improvements in 
Table 2 Characteristics of FEV1 matched subgroups with RV/TLC   55% (Hyp+) OR   55% (Hyp–) and the effect of tiotropium
 Hyp+ (n = 20)  Hyp– (n = 20)  p-value
     Hyp+ vs Hyp–
     at  baseline
Age (yrs)  70 ± 2      65 ± 2        0.1
Height (cm)  170 ± 1      175 ± 1       0.009
COPD diagnosis (yrs)  7 ± 2      6 ± 2        0.1
Packyears (py)  57 ± 4      51 ± 9        0.1
  Baseline  3 wks   6 wks   Baseline  3 wks   6 wks
   tiotropium  tiotropium    tiotropium  tiotropium
FEV1 (%pred)  55 ± 2  59 ± 3 *  59 ± 2 †  58 ± 3  58 ± 3  60 ± 3   0.1
FEV1 (L)  1.46 ± 0.07  1.56 ± 0.08 *  1.58 ± 0.08 †  1.80 ± 0.11  1.82 ± 0.11  1.87 ± 0.12  0.02
FEV1/FVC (%)  50 ± 2  51 ± 2  50 ± 2  49 ± 3  48 ± 3  49 ± 3   0.1
FEF75 (%pred)  14 ± 1  14 ± 2  14 ± 1  18 ± 2  16 ± 2  18 ± 1  0.09
Kco (%pred)  71 ± 5  71 ± 6  71 ± 6  68 ± 5  67 ± 4  67 ± 5   0.1
sGaw (L/s/cmH2O/L) 0.044  ± 0.006  0.048 ± 0.004  0.047 ± 0.004  0.050 ± 0.005  0.049 ± 0.004  0.050 ± 0.004   0.1
RVpl (ml)  3598 ± 140  3802 ± 262  3594 ± 151  3106 ± 169  3131 ± 196  3050 ± 193  0.03
TLCpl (ml)  6272 ± 219  6573 ± 302  6433 ± 243  6535 ± 260  6603 ± 319  6518 ± 303   0.1
ICpl (ml)  1808 ± 107  1874 ± 77  1896 ± 110  2201 ± 158  2203 ± 158  2249 ± 152  0.05
IC (ml) 2088  ± 103  2232 ± 96  2315 ± 122 †  2502 ± 108  2489 ± 116  2526 ± 137  0.01
Sacin (L−1) 0.400  ± 0.027  0.382 ± 0.028  0.402 ± 0.029  0.321 ± 0.029  0.346 ± 0.031  0.326 ± 0.037  0.05
Scond (L−1) 0.087  ± 0.006  0.082 ± 0.008  0.088 ± 0.010  0.089 ± 0.008  0.084 ± 0.008  0.101 ± 0.009   0.1
FRCmbw (ml)  3685 ± 151  3595 ± 161  3547 ± 154  3721 ± 170  3737 ± 171  3703 ± 136   0.1
Total symptom score  3.2 ± 0.4  2.1 ± 0.4 *  1.4 ± 0.2 †  3.3 ± 0.3  1.7 ± 0.2 †  1.3 ± 0.2 †   0.1
(0–12)
MRC dyspnea score  1.9 ± 0.2  1.8 ± 0.2  1.7 ± 0.2  1.6 ± 0.2  1.7 ± 0.2  1.9 ± 0.3   0.1
(1–5)
VAS dyspnea score  4.6 ± 0.6  3.0 ± 0.5 *  2.6 ± 0.6 †  3.0 ± 0.6  2.9 ± 0.6  2.6 ± 0.5   0.1
(0–10)
Notes: All averages (±SEM) refer to data prior to tiotropium intake on the study day; same abbreviations as in Table I. Signiﬁ  cant changes from baseline (within Hyp+ and 
Hyp– groups): *p   0.05; † p   0.01.International Journal of COPD 2007:2(4) 633
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ventilation heterogeneity of the conductive airways were 
unrelated to changes in hyperinﬂ  ation.
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Packyears (py)  60 ± 6      50 ± 12       >0.1
  Baseline  3 wks   6 wks   Baseline  3 wks   6 wks
   tiotropium  tiotropium    tiotropium  tiotropium
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Appendix
Ventilation distribution testing
The ventilation distribution test, ie, the multiple breath 
washout (MBW), was carried out using a computer-con-
trolled bag-in-box breathing assembly. Tidal volume was 
targeted at 1 L and after a period of air breathing with stable 
end-expiratory lung volume at functional residual capacity, 
inspired air was switched to the test gas mixture. The test 
gas mixture consisted of pure O2, and 1 L tidal breathing 
continued for 20–25 breaths depending on the subject’s lung 
volume (dilution); exhaled N2 concentration tracings were 
analyzed. From the MBW N2 tracings, indices Scond and 
Sacin were derived to represent the conductive and acinar 
components of ventilation heterogeneity, respectively, using 
an analysis that can be summarized as follows. During each 
expiration, the N2 phase III slope is computed and normal-
ized by the mean expired N2 concentration. This leads to a 
normalized N2 slope (Sn) which increases as a function of 
breath number or lung turnover (Figure A1); lung turnover 
is determined as the cumulative expired volume divided by 
ventilated functional residual capacity, which is computed 
from a mass balance of the MBW test. On theoretical grounds 
it can be shown that: (a) the rate of rise of the Sn curve is 
due to the convective ﬂ  ow asynchrony between lung units 
larger than acini, thus, due to heterogeneity originating in the 
conductive airways; (b) the offset of the Sn curve is mainly 
determined by diffusion-convection dependent heterogeneity 
generated in the acinar airways. Hence, Scond is simply com-
puted as the rate of Sn increase as a function of lung turnover, 
between 1.5 and 6 lung turnovers. Then, Sacin is computed as 
the Sn value of the ﬁ  rst MBW expiration minus a correction 
term to discard any conductive lung zone contribution; this 
correction term equals the lung turnover corresponding to 
the ﬁ  rst breath, multiplied by Scond. Illustrated in Figure A1 
are two selected COPD patients who show a similar Sacin 
(0.39 L–1 and 0.41 L−1) and markedly different Scond (open 
and closed circles correspond to respectively Scond = 0.049 
L−1 and closed circles to Scond = 0.098 L−1). A normalized 
slope curve corresponding to a typical normal subject (dotted 
line) corresponds to Sacin and Scond values of 0.072 L−1 and 
0.029 L−1, respectively.
The theory of MBW phase III slope analysis leading to 
indices Scond and Sacin implies that ventilation heterogeneity 
can be attributed to different lung depths, ie, to the conductive 
and acinar lung zone, respectively, and that Scond and Sacin 
are intrinsically independent and are not comparable between 
each other (despite having the same dimension, L–1). Finally, 
since Scond and Sacin are derived from phase III slopes, their 
value increases when ventilation heterogeneity increases. In 
particular, Sacin will increase if ventilation heterogeneity is 
increased in the acinar lung zone, due to an alteration of the 
intra-acinar asymmetry (eg, unequal narrowing of affected 
respiratory bronchioles). On the other hand, Scond will increase 
when heterogeneous narrowing of conductive airways induces 
an alteration in the speciﬁ  c ventilation and/or ﬂ  ow asynchrony 
between the lung units subtended by these airways proximal to 
the terminal bronchioles.
An increase in Scond reﬂ  ects uneven narrowing of either 
the large or the small conductive airways, or both. A dispro-
portionate Scond increase with respect to the decrease of large 
airway parameters such as FEV1 or speciﬁ  c airway conduct-
ance can be used to identify the small airways component 
of conductive lung zone heterogeneity. An increase in Sacin 
represents a change in intra-acinar structural asymmetry, 
due to uneven narrowing of respiratory bronchioles or due to 
partial destruction of parenchyma, or both. Again, a dispropor-
tionate Sacin increase with respect to a decrease of diffusion 
capacity enables the identiﬁ  cation of the nonemphysematous 
component of acinar lung zone heterogeneity.
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Figure A1 Normalized N2 phase III slopes (mean ± SD) as a function of lung 
turnover obtained in two patients participating in this study (open and closed 
circles); also represented is an idealized curve corresponding to normal normalized 
N2 phase III slopes (dotted line).